« Government Targeting Pharmaceutical Executives with Renewed Enthusiasm | Main | FDA REMS: Blue Print for Prescriber Continuing Education Program for Extended Release-Long Acting Opioids »

November 07, 2011

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00e5520572bb8834015436aec117970c

Listed below are links to weblogs that reference NY Times: Medical Experts on Guidelines Panels - Not Welcome?:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

"Freedom from experts is not the answer. A principled expert with experience, in the end is good for patient care and should be a welcome addition to guidelines panels."

Agreed. At the end of the day, it is impossible to get completely free from any potential conflicts of interest. The only way to do that is to select individuals who are so ignorant of medical trials altogether that their opinion on such would be next to worthless.

The comments to this entry are closed.

Sponsors

Enter your Email:
Preview | Powered by FeedBlitz

November 2014

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30